Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
QNCX Stock Chart & Stats
$1.86
-$0.07(-3.61%)
At close: 4:00 PM EST
$1.86
-$0.07(-3.61%)
Day’s Range― - ―
52-Week Range$0.72 - $2.45
Previous CloseN/A
Volume30.57K
Average Volume (3M)359.59K
Market Cap
$99.91M
Enterprise Value$59.81M
Total Cash (Recent Filing)$34.71M
Total Debt (Recent Filing)$17.38M
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Nov 13, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding53,713,800
10 Day Avg. Volume552,038
30 Day Avg. Volume359,590
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue356.03
Enterprise Value/Gross Profit-866.84
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$8.00Price Target Upside330.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Patient BenefitThe AIDE technology used by Quince allows for a simple and safe point-of-care treatment, which is beneficial for patients avoiding daily steroid side effects.
Study EnrollmentThe ongoing P3 study of eDSP in ataxia-telangiectasia has exceeded 75% enrollment, indicating strong progress.
Technology AdvantageThe company's AIDE technology allows for the effective delivery of dexamethasone with fewer safety concerns compared to traditional methods.
Bears Say
Enrollment ChallengesEnrollment in the P3 NEAT study is slower than expected, which has led management to consider concluding enrollment early.
Financial PerformanceQuince reported 4Q24 and 2024 results with a net loss of ($12.5M) and ($56.8M), respectively, which included $25.4M in non-cash items.
Past Study OutcomesThere is a history of a prior P3 study missing its primary endpoint, though a subgroup of kids aged 6-9 reached statistical significance.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.72 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $99.91M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Nov 13, 2025 which is in 24 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.252 by -$0.088.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 53,713,800 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.252. Following the earnings report the stock price went up 14.375%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
Quince Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (330.11% Upside)
$8.00 (330.11% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.84%
12-Months-Change
Fundamentals
Return on Equity
-167.04%
Trailing 12-Months
Asset Growth
-13.07%
Trailing 12-Months
Company Description
Quince Therapeutics
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$8.00
▲(330.11% Upside)
Technical Analysis
Ownership Overview
15.18% Insiders
3.53% Mutual Funds
6.44% Other Institutional Investors
72.23% Public Companies and
Individual Investors